Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Idiopathic pulmonary fibrosis is a progressive lung disease with a high mortality rate. Because the signaling pathways activated by several tyrosine kinase receptors have been shown to be involved in lung fibrosis, it has been suggested that the inhibition of these receptors may slow the progression of idiopathic pulmonary fibrosis. METHODS: In a 12-month, phase 2 trial, we assessed the efficacy and safety of four different oral doses of the tyrosine kinase inhibitor BIBF 1120 as compared with placebo in patients with idiopathic pulmonary fibrosis. The primary end point was the annual rate of decline in forced vital capacity (FVC). Secondary end points included acute exacerbations, quality of life (measured with the St. George's Respiratory Questionnaire [SGRQ]), and total lung capacity. RESULTS: A total of 432 patients underwent randomization to receive one of four doses of BIBF 1120 (50 mg once a day, 50 mg twice a day, 100 mg twice a day, or 150 mg twice a day) or placebo. In the group receiving 150 mg of BIBF 1120 twice a day, FVC declined by 0.06 liters per year, as compared with 0.19 liters per year in the placebo group, a 68.4% reduction in the rate of loss with BIBF 1120 (P = 0.06 with the closed testing procedure for multiplicity correction; P = 0.01 with the hierarchical testing procedure). This dose also resulted in a lower incidence of acute exacerbations, as compared with placebo (2.4 vs. 15.7 per 100 patient-years, P = 0.02) and a small decrease in the SGRQ score (assessed on a scale of 0 to 100, with lower scores indicating better quality of life) as compared with an increase with placebo (-0.66 vs. 5.46, P = 0.007). Gastrointestinal symptoms (which led to more discontinuations in the group receiving 150 mg twice a day than in the placebo group) and increases in levels of liver aminotransferases were more frequent in the group receiving 150 mg of BIBF 1120 twice daily than in the placebo group. CONCLUSIONS: In patients with idiopathic pulmonary fibrosis, BIBF 1120 at a dose of 150 mg twice daily, as compared with placebo, was associated with a trend toward a reduction in the decline in lung function, with fewer acute exacerbations and preserved quality of life. (Funded by Boehringer Ingelheim; ClinicalTrials.gov number, NCT00514683 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The Bayesian approach incorporated dynamic borrowing of historical placebo data from several external IPF trials, including the ASCEND, INPULSIS, and TOMORROW studies (Figures E2 and E3).2,3,13”
From Deupirfenidone Compared with Pirfenidone and Placebo in Idiopathic Pulmonary Fibrosis (ELEVATE-IPF): a Phase 2b Randomized Placebo-Controlled Trial (2026) · cites this paper as [13]
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
The St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,628
Selman, M., King, T. E., & Pardo, A. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-2-200101160-00015 · Cited by 1,786
Self-citationClinical course and prediction of survival in idiopathic pulmonary fibrosis
Ley, B., Collard, H. R., & King, T. E. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201006-0894ci · Cited by 1,765
Acute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, H. R., Moore, B. B., Flaherty, K. R., Brown, K. K., Kaner, R. J., King, T. E., Lasky, J. A., Loyd, J. E., Noth, I., Olman, M. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-463pp · Cited by 1,130
Self-citationBIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
St. George's Respiratory Questionnaire: MCID
Jones, P. W. (2005) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.1081/copd-200050513 · Cited by 855
The Clinical Course of Patients with Idiopathic Pulmonary Fibrosis
Martinez, F. J., Safrin, S., Weycker, D., Starko, K. M., Bradford, W. Z., King, T. E., Flaherty, K. R., Schwartz, D. A., Noble, P. W., Raghu, G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-12_part_1-200506210-00005 · Cited by 622
Self-citationBois, R. M. D., Weycker, D., Albera, C., Bradford, W. Z., Costabel, U., Kartashov, A., Lancaster, L., Noble, P. W., Sahn, S. A., Szwarcberg, J., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201007-1179oc · Cited by 465
Self-citation
Cited by
Items 901–1,000 of 1,000
Fahim, A. (2021) · The Clinical Respiratory Journal · doi:10.1111/crj.13322 · Cited by 1
Bleinc, A., Blin, T., Legué, S., Mankikian, J., Plantier, L., & Marchand-Adam, S. (2023) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2023.03.004 · Cited by 2
Ono, M., Kobayashi, S., Hanagama, M., Ishida, M., Sato, H., Okutomo, K., Shirai, Y., Takahashi, K., Yamada, M., Fujino, N., et al. (2024) · Medicine · doi:10.1097/md.0000000000038920 · Cited by 1
Diagnosis and Management of Fibrotic Interstitial Lung Disease: A Primer
Sridhar, M., & Kulkarni, T. (2024) · Touch reviews in respiratory & pulmonary diseases. · doi:10.17925/usprd.2024.9.1.3 · Cited by 1
Current approaches for the treatment of chronic respiratory disorders and limitations
Yeung, S., Loo, C., Saeid, A. B., & Lee, W. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-27345-2.00002-3 · Cited by 4
Breaking new ground in pulmonary fibrosis: Targeting Pathways and Therapeutic Innovations
Mishra, S. (2025) · The Journal of Association of Chest Physicians · doi:10.4103/jacp.jacp_1_25 · Cited by 1
Zheng, J., zhou, N., & Pang, D. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1561440 · Cited by 1
Tagami, Y., Kawai, M., Okamura, K., & Kitamura, H. (2025) · Journal of Clinical Question · doi:10.69854/jcq.2025.0021 · Cited by 1
Optimized Synthetic Flavonols Support Senescence Clearance and Lung Fibrosis Resolution
Meridew, J. A., Vu, J. A., Chow, D., Espinosa, A. M. D., Saraf, N., Gao, A. Y., Espíndola‐Netto, J. M., Dresler, S. R., Whaley, M. G., Choi, K. M., et al. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00231 · Cited by 2
Lee, J. H., Park, S., & Yoon, H. (2025) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666251390672 · Cited by 2
Borghetti, P., D’Angelillo, R. M., Facheris, G., Borghesi, A., Bruni, A., Ceruti, P., Ferrari, K., Filippi, A. R., Ramella, S., Signorelli, D., et al. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108807 · Cited by 2
Yang, X., Wang, Y., Li, L., Lei, Q., Xiang, L., Zhang, X., Liu, J., Cao, Y., Li, H., & Li, X. (2026) · Cellular Signalling · doi:10.1016/j.cellsig.2026.112364 · Cited by 1
Fares, W. H., & Castagna, M. (2026) · Journal of Aerosol Medicine and Pulmonary Drug Delivery · doi:10.1177/19412711251414386 · Cited by 1
The human pathome shows sex and tissue specific aging patterns
Ezra, M. B., Garbrecht, J. B., Rasmussen, N., Mediavilla, M. C., Heckenbach, I., Petr, M. A., Bakula, D., Mortensen, L. H., & Scheibye‐Knudsen, M. (2026) · npj Aging · doi:10.1038/s41514-025-00307-z · Cited by 2
Sethi, P. P., Gupta, A. K., Sudan, A., Baweja, A., Ranka, R., Khapre, M. P., Manna, S., Kant, R., & Pai, V. S. (2026) · Indian Journal of Rheumatology · doi:10.1177/09733698251403238 · Cited by 1
Self-citationMariniello, D. F., Perrotta, F., Picone, C., Liakouli, V., Zamparelli, S. S., Stella, G. M., Reginelli, A., Rea, G., Bianco, A., & D’Agnano, V. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1741725 · Cited by 1
Yin, Y., Wu, X., Liu, Z., Luo, Y., Jing, M., Jing, K., Li, Q., Wang, F., & Huang, J. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1761899 · Cited by 1
Brugière, O., Hirschi, S., Reynaud‐Gaubert, M., Bunel, V., Demant, X., Pavec, J. L., Falque, L., Mohammed, N. S., Tardivon, C., & Couffignal, C. (2026) · Trials · doi:10.1186/s13063-025-09314-7 · Cited by 1
Alveolar type II cell therapy ameliorates pulmonary fibrosis by reprogramming macrophage activation
Guillamat‐Prats, R., Gay-Jordi, G., Duch, P., Gea‐Sorlí, S., Sánchez-López, L. I., Peinado, V. I., & Serrano‐Mollar, A. (2026) · Inflammation and Regeneration · doi:10.1186/s41232-026-00434-4 · Cited by 1
Wang, W., Zhang, Y., He, F., Sun, L., Li, H., Liu, R., Zhong, G., Zhang, L., Li, A., Feng, M., et al. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02753-x · Cited by 1
Developments into understanding the pathogenesis of systemic sclerosis
Hunzelmann, N. (2013) · Expert Review of Dermatology · doi:10.1586/edm.13.8 · Cited by 1
Management of Idiopathic Pulmonary Fibrosis
Cerri, S., Spagnolo, P., Luppi, F., Sgalla, G., & Richeldi, L. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-48024-6.00004-5 · Cited by 1
Self-citationNintedanib in idiopathic pulmonary fibrosis: a guide to its use
Keating, G. M. (2015) · Drugs & Therapy Perspectives · doi:10.1007/s40267-015-0240-y · Cited by 1
Perspectivas en el tratamiento de la fibrosis pulmonar idiopática
Morell, F., & Villar, A. (2012) · Archivos de Bronconeumología · doi:10.1016/s0300-2896(12)70046-7 · Cited by 1
Montero, Á. (2015) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2015.02.006 · Cited by 1
Clinical trials in idiopathic pulmonary fibrosis: update and perspectives
Baroke, E., Maharaj, S. S., & Kolb, M. R. J. (2011) · Clinical Investigation · doi:10.4155/cli.11.155 · Cited by 2
Pharmacotherapy in idiopathic pulmonary fibrosis
Acharya, G., Arya, S., Badal, S., Kumar, D., & Samdariya, S. (2014) · International Journal of Basic & Clinical Pharmacology · doi:10.5455/2319-2003.ijbcp20141012 · Cited by 1
New Treatments for Idiopathic Pulmonary Fibrosis, Empyema, and Chronic Obstructive Pulmonary Disease
Brito, V., NAIR, G. B., & Brar, N. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201110-1871rr · Cited by 1
Interstitielle Lungenerkrankungen: Differentialdiagnose und Therapie
Behr, J. (2013) · Der Pneumologe · doi:10.1007/s10405-012-0613-z · Cited by 1
Maher, T. M., & Spagnolo, P. (2016) · European Respiratory Society eBooks · doi:10.1183/2312508x.10006615 · Cited by 1
Drug Development and Regulatory Considerations for SSc Therapies
Wright, T. M. (2016) · Springer eBooks · doi:10.1007/978-3-319-31407-5_43 · Cited by 1
Nintedanib—Nowa opcja terapeutyczna dla chorych na samoistne włóknienie płuc
Majewski, S., & Piotrowski, W. J. (2016) · Advances in respiratory medicine · doi:10.5603/arm.46993 · Cited by 1
Akute Exazerbation der IPF – revidierte Definition und Diagnosekriterien
Markart, P., & Günther, A. (2017) · Pneumo News · doi:10.1007/s15033-017-0601-4 · Cited by 1
The Role of Mesenchymal Stromal Cells in Idiopathic Pulmonary Fibrosis
Río, C. (2016) · International Journal of Stem cell Research & Therapy · doi:10.23937/2469-570x/1410030 · Cited by 1
Pathobiology of Novel Approaches to Treatment
Puglisi, S., & Vancheri, C. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-48024-6.00002-1 · Cited by 1
The Hospitalized Patient with Interstitial Lung Disease: A Hospitalist Primer
Farrand, E. D., Shah, R., & Collard, H. R. (2017) · Journal of Hospital Medicine · doi:10.12788/jhm.2774 · Cited by 1
Condoluci, C., Inchingolo, R., Mastrobattista, A., Comes, A., Golfi, N., Boccabella, C., & Richeldi, L. (2017) · European Respiratory Society eBooks · doi:10.1183/2312508x.10002017 · Cited by 2
Self-citationTriple kinase inhibitor with phosphodiesterase-5 inhibitor for idiopathic pulmonary fibrosis
Kishaba, T. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.10.84 · Cited by 1
The Hypoxic Adenosine Response and Inflammation in Lung Disease
Philip, K., & Blackburn, M. R. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813832-8.00002-9 · Cited by 1
Real-World Comprehensive Disease Management of Patients With Idiopathic Pulmonary Fibrosis
Mason, W. R., McLaughlin, S., Dedopoulos, S., Mahoney, E., Meadows, T., Stauffer, J. L., & LANCASTER, L. H. (2019) · Current Respiratory Medicine Reviews · doi:10.2174/1573398x15666190212155051 · Cited by 1
Galindo, J. L., Celis-Preciado, C. A., Pontificia Universidad Javeriana. Bogotá, C., Mejía, M. E., & Unidad de Enfermedades Pulmonares Intersticiales. Instituto Nacional de Enfermedades Respiratorias, I. C. V. C. D. M. (2018) · Investigación Clínica · doi:10.22209/ic.v59n4a07 · Cited by 1
Scott, D. A., Loveman, E., Colquitt, J. L., & O’Reilly, K. M. (2019) · Medicina · doi:10.3390/medicina55080443 · Cited by 1
Patete, C. L., Toonkel, R. L., & Glassberg, M. K. (2019) · Springer eBooks · doi:10.1007/978-3-030-29403-8_7 · Cited by 1
Acute Exacerbations in Patients With Idiopathic Pulmonary Fibrosis
Kim, D. S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-48024-6.00011-2 · Cited by 1
Self-citationCarrera, L. G., & Álvarez-Sala, J. L. (2016) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2015.06.004 · Cited by 2
Idiopathic Interstitial Pneumonias
Ryu, J. H., Selman, M., Colby, T. V., & King, T. E. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-3383-5.00063-4 · Cited by 2
Self-citationReal-World Data on Bleeding Risk and Anticoagulation in Patients with IPF Treated with Antifibrotics
Bendstrup, E. M., & Kalluri, M. (2020) · Drug Safety · doi:10.1007/s40264-020-00991-8 · Cited by 1
Nintedanib for the treatment of idiopathic pulmonary fibrosis: An Indian perspective
Kishore, K., Singh, A., Verma, A., & Singh, A. (2020) · The Journal of Association of Chest Physicians · doi:10.4103/jacp.jacp_35_19 · Cited by 1
Current and future treatment for idiopathic pulmonary fibrosis
Choi, W.-I. (2021) · Journal of Korean Medical Association · doi:10.5124/jkma.2021.64.4.256 · Cited by 1
Progressive Fibrosis in Interstitial Lung Diseases—Proposed Definition and Management
Martusewicz-Boros, M. M., & Piotrowski, W. J. (2021) · Advances in respiratory medicine · doi:10.5603/arm.a2021.0103 · Cited by 1
Sjögren’s Syndrome and The Respiratory System: A Comprehensive Approach
Mahmood, F., Ehtesham, M., Bokhari, S. M. M. A., & Peredo-Wende, R. (2021) · Journal of Lung Health and Diseases · doi:10.29245/2689-999x/2021/2.1176 · Cited by 1
Environmental and Pollution Related Risks for Hypersensitivity Pneumonitis
Ferraro, V., & Morisset, J. (2022) · Respiratory medicine · doi:10.1007/978-3-030-90185-1_5 · Cited by 1
Review on Idiopathic Pulmonary Fibrosis
Kuchekar, S., & Jadhav, R. V. (2022) · Asian Journal of Research in Pharmaceutical Sciences · doi:10.52711/2231-5659.2022.00008 · Cited by 1
Prasse, A. (2016) · European Respiratory Society eBooks · doi:10.1183/2312508x.10005615 · Cited by 1
Idiopathic Pulmonary Fibrosis: What Is the Best Treatment?
Wu, X., Kaner, R. J., & Martínez, F. J. (2017) · Barcelona Respiratory Network · doi:10.23866/brnrev:2017-0041 · Cited by 1
Rowlands, B., Mehta, P., & Gunawardena, H. (2021) · Indian Journal of Rheumatology · doi:10.4103/0973-3698.332986 · Cited by 1
Regulation of MicroRNA Expression in Scleroderma and Idiopathic Pulmonary Fibrosis: A Research Study
Badyal, R., Whalen, B. A., Singhera, G. K., Sahin, B., Keen, K. J., Ryerson, C. J., Wilcox, P., & Dunne, J. V. (2023) · Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal · doi:10.26685/urncst.442 · Cited by 1
Pulmonary fibrosis treatment in children – What have we learnt from studies in adults?
Jia, M. B., & Fitzgerald, D. A. (2023) · Paediatric Respiratory Reviews · doi:10.1016/j.prrv.2023.12.001 · Cited by 3
DESAFIOS E PERSPECTIVAS NA GESTÃO DA FIBROSE PULMONAR IDIOPÁTICA: RUMO A TERAPIAS MAIS EFICAZES
Silva, A. S., Bomfim, V. V. B. D. S., Brito, I. R. A. X., Bucciaroni, R., Oliveira, P. M. R. E., Bezerra, B. W. W., Costa, L. M. M., & Neto, H. J. R. (2024) · Revista Ibero-Americana de Humanidades, Ciências e Educação · doi:10.51891/rease.v10i4.13558 · Cited by 1
Alshneikat, M., Alnajjar, Z., Obeidat, O. I., Al‐Tanjy, A., Alsokhni, A., & Innabi, A. (2024) · JAP Academy Journal · doi:10.58877/japaj.v2i1.125 · Cited by 1
Post-COVID respiratory disorders
Викторович, Л. И., Glushkova, T. V., & Esaulova, N. A. (2024) · doi:10.18093/978-5-6048754-6-9-2024-2-501-506 · Cited by 1
Erten, H. Ç. (2024) · Eurasian Journal of Pulmonology · doi:10.14744/ejp.2024.8005 · Cited by 1
Tetikkurt, C. (2024) · doi:10.69860/nobel.9786053359517 · Cited by 1
Hartmann, S., Janssen, J. M., Ribbing, J., Stowasser, S., & Korell, J. (2025) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.70132 · Cited by 1
Therapie der idiopathischen Lungenfibrose
Behr, J. (2013) · Der Pneumologe · doi:10.1007/s10405-012-0607-x · Cited by 1
Valeyre, D., Jeny, F., Freynet, O., & Nunès, H. (2016) · European Respiratory Society eBooks · doi:10.1183/2312508x.10004915 · Cited by 1
Idiopathic Pulmonary Fibrosis: Clinical Behavior, Pathogenic Mechanisms and Therapeutic Approach
Selman, M., & Pardo, A. (2015) · Barcelona Respiratory Network · doi:10.23866/brnrev:2015-m0003 · Cited by 1
Self-citationCottin, V., Crestani, B., Cadranel, J. L., Cordier, J. F., Marchand-Adam, S., Prévôt, G., Wallaert, B., Bergot, E., Camus, P., Dalphin, J., et al. (2017) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2017.07.020 · Cited by 1
Kirsten, D., de Vries, U., Costabel, U., Koschel, D., Bonella, F., Günther, A., Behr, J., Claussen, M., Schwarz, S., Prasse, A., et al. (2021) · Pneumologie · doi:10.1055/a-1334-2745 · Cited by 1
Self-citationLara, A., & Schwarz, M. I. (2016) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2015-000124 · Cited by 1
Costabel, U. (2013) · Der Pneumologe · doi:10.1007/s10405-012-0648-1 · Cited by 1
Self-citationProgress in the Diagnosis and Treatment of Idiopathic Pulmonary Fibrosis
Schwartz, R. S., & Glassberg, M. K. (2016) · touchREVIEWS in Respiratory & Pulmonary Diseases · doi:10.17925/usrpd.2016.01.01.22 · Cited by 1
Clinical approach to gastro-oesophageal reflux in idiopathic pulmonary fibrosis
Jones, R. (2016) · Cited by 1
The human pathome shows sex and tissue specific aging patternsPreprint
Scheibye‐Knudsen, M., Ezra, M. B., Garbrecht, J. B., Rasmussen, N., Heckenbach, I., Petr, M. A., Bakula, D., & Mortensen, L. H. (2023) · Research Square · doi:10.21203/rs.3.rs-2652110/v1 · Cited by 1
d’Audigier, C. (2013) · theses.fr (ABES) · doi:10.70675/19800b70z5208z47c4z97e8z80d335c3a541
Efficacy of non‐invasive ventilation in acute exacerbation of idiopathic interstitial pneumonia
Yokoyama, T., & Tsushima, K. (2012) · Respirology · doi:10.1111/j.1440-1843.2012.02224.x
Munar, M. A., Pantoja, J. A., Santacruz, J. C., Villate, A. M., Bastidas, A., & Giraldo‐Cadavid, L. F. (2012) · Revista Med · doi:10.18359/rmed.1203 · Cited by 1
Current and Emerging Treatment Options in Interstitial Lung Disease
Maher, T. M. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0770-0_14
Concas, A., Battistella, L., Mastrotto, C., Arcaro, G., Paladini, L., Gallan, F., Marchi, M. R., & Vianello, A. (2014) · European Respiratory Journal · doi:10.1183/13993003/erj.44.suppl_58.p2960
INIBIDORES DAS TIROSINACINASES NA TERAPÊUTICA FARMACOLÓGICA
Saraiva, S., Morgado, S., & Morgado, M. (2013) · Revista portuguesa de farmacoterapia · doi:10.25756/rpf.v5i3.44
Update on New Treatments for Idiopathic Pulmonary Fibrosis
DeGrado, J. R., & Gilmore, J. F. (2015) · Current Emergency and Hospital Medicine Reports · doi:10.1007/s40138-015-0076-8
Diagnóstico y tratamiento de la fibrosis pulmonar idiopática
Ancochea, J., & Valenzuela, C. (2012) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0304-5412(12)70481-x
Clinical trials of idiopathic pulmonary fibrosis: choosing the (right) primary end point
Spagnolo, P., & Luppi, F. (2013) · Clinical Investigation · doi:10.4155/cli.13.107
Clinical trials in idiopathic pulmonary fibrosis: where we have been and where we are going
Luppi, F., Spagnolo, P., Cerri, S., Sgalla, G., & Richeldi, L. (2012) · Current Respiratory Care Reports · doi:10.1007/s13665-012-0030-0
Self-citationIdiopathische pulmonale Fibrose
Markart, P., Wygrecka, M., & Günther, A. (2015) · Pneumo News · doi:10.1007/s15033-014-0003-9
Ancochea, J., Pérez, T. A., Gutiérrez, M. D. V. S., & Valenzuela, C. (2014) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0304-5412(14)70847-9
Pneumopathies interstitielles diffuses et sarcoïdose
Macey, J. (2012) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(12)70177-5
Update on idiopathic interstitial pneumonias
Ryu, J. (2014) · Shortness of Breath · doi:10.11138/sob/2014.3.1.00
Update to the guidelines for selection of lung-transplant candidates
Silhan, L. L., & Orens, J. B. (2014) · Current Respiratory Care Reports · doi:10.1007/s13665-014-0078-0
Hope for Disease-Modifying Treatment of Systemic Sclerosis/Scleroderma
Michel, M. C. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.213520comm
Pulmonary arterial hypertension in connective tissue
Hassoun, M., Maurer, B., Distler, O., & Hassoun, P. M. (2012)
Treatment of radiation fibrosis
Westbury, C. (2015) · Journal of Tumor
“The Long and Winding Road” seeking specific drugs for idiopathic pulmonary fibrosis
Munakata, M. (2015) · Respiratory Investigation · doi:10.1016/j.resinv.2015.12.001
Studies on TGF-β family signalling in the diseased lung tissue
Leppäranta, O. (2012) · Helda - University of Helsinki Institutional Repository
Traitement médical de la fibrose pulmonaire idiopathique : de nouvelles perspectives
Bouvry, D., & Jouneau, S. (2014) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(14)70619-6
Fibrose pulmonaire idiopathique : une nouvelle ère, de nouveaux défis
Cottin, V. (2014) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2014.07.009
What is the purpose of launching World Journal of Respirology?
Rosell, R. (2011) · World Journal of Respirology · doi:10.5320/wjr.v1.i1.1
Sisson, T. H., Osterholzer, J. J., Christensen, P. J., Lama, V. N., Horowitz, J. C., Subbotina, N., Murdock, B. J., Olszewski, M. A., & Simon, R. H. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a4921
Metadata
- Authors
- Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., Brun, M., Gupta, A., Juhel, N., Klüglich, M., & du Bois, R. M.
- Affiliations
- University of Modena and Reggio Emilia (IT)
- Ruhrlandklinik (DE)
- Asan Medical Center (KR)
- Royal Brompton Hospital (GB)
- Michigan Medicine (US)
- Duke Medical Center (US)
- University of Washington (US)
- Boehringer Ingelheim (France) (FR)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-09-22
- Volume
- 365
- Issue
- 12
- Pages
- 1079-1087
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2152974152
- Cited by
- 1,157
- References
- 22
- Citations by year
- 2026: 32 · 2025: 50 · 2024: 79 · 2023: 74 · 2022: 83 · 2021: 86 · 2020: 73 · 2019: 72 · 2018: 91 · 2017: 102 · 2016: 88 · 2015: 100 · 2014: 71 · 2013: 80 · 2012: 61
- FWCI
- 60.67
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- idiopathic pulmonary fibrosis, nintedanib, tyrosine kinase inhibitors, forced vital capacity decline, lung fibrosis progression, acute exacerbation, quality of life, gastrointestinal adverse effects, liver aminotransferases, dose comparison, St George's Respiratory Questionnaire, total lung capacity, drug safety and efficacy
- MeSH terms
- Adult, Aged, Alanine Transaminase, Aspartate Aminotransferases, Enzyme Inhibitors, Female, Humans, Indoles, Liver, Male, Middle Aged, Protein-Tyrosine Kinases, Vital Capacity, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.